Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.31% | 8.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.43% | 45.10% | |||
| Operating Income | -12.43% | -45.10% | |||
| Income Before Tax | -193.77% | 30.38% | |||
| Income Tax Expenses | -1,110.59% | 107.81% | |||
| Earnings from Continuing Operations | -172.84% | 17.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -172.84% | 17.22% | |||
| EBIT | -12.43% | -45.10% | |||
| EBITDA | -- | -45.17% | |||
| EPS Basic | -98.51% | 37.41% | |||
| Normalized Basic EPS | -144.31% | 64.33% | |||
| EPS Diluted | -98.51% | 37.41% | |||
| Normalized Diluted EPS | -144.31% | 64.33% | |||
| Average Basic Shares Outstanding | 37.44% | 32.27% | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||